How should possible acute anterior uveitis (iriditis) be evaluated and treated?

Evaluation and Treatment of Possible Acute Anterior Uveitis (Iriditis)

Urgent ophthalmology referral is required for any patient with suspected acute anterior uveitis presenting with eye pain, photophobia, blurred vision, or redness to confirm diagnosis via slit-lamp examination and initiate immediate topical corticosteroid therapy.

Immediate Clinical Assessment

When evaluating possible iriditis, distinguish between:

• Acute Anterior Uveitis (AAU): Sudden onset, typically unilateral, with severe eye pain, photophobia, redness, and blurred vision. Often HLA-B27 associated and linked to spondyloarthritis 1, 2
• Chronic Anterior Uveitis (CAU): Insidious onset, often bilateral and asymptomatic until complications develop. Common in juvenile idiopathic arthritis 1
• Simple episcleritis: Mild pain, hyperemia without visual changes, photophobia, or severe pain—does not require specialist referral 2

Critical red flags requiring immediate ophthalmology evaluation 2:

• Moderate to severe eye pain
• Photophobia
• Blurred or diminished vision
• Visual disturbance of any kind

Diagnostic Confirmation

Slit-lamp examination by an ophthalmologist is mandatory to:

• Confirm anterior chamber cells (≥1+ cells = 6-15 cells per 1mm × 1mm slit beam) 1, 3
• Identify keratic precipitates, flare, or hypopyon
• Detect complications: posterior synechiae, cataract, elevated intraocular pressure, cystoid macular edema 1, 4
• Differentiate from scleritis, intermediate/posterior uveitis 2

Laboratory Investigation Strategy

For severe, bilateral, recurrent, or chronic anterior uveitis 5, 6:

First-line screening (all patients):

• Syphilis serology (mandatory in all uveitis) 6
• HLA-B27 (for unilateral acute non-granulomatous uveitis) 7, 6

Additional testing guided by clinical presentation 6:

• Serum angiotensin-converting enzyme (chronic uveitis, suspected sarcoidosis)
• Interferon-gamma release assay (tuberculosis screening in chronic cases)
• Chest imaging if systemic symptoms present

Avoid shotgun testing—investigations without clinical orientation are costly and unhelpful 5, 6.

Treatment Algorithm

For Acute Anterior Uveitis (AAU)

Initial therapy 1, 4, 2:

• Topical prednisolone acetate 1% (or dexamethasone) is first-line treatment 4, 1
• Frequency: Initially hourly while awake, then taper based on response
• Duration: Typically 6-12 weeks for AAU episodes 1

For AAU in patients on systemic immunosuppression for spondyloarthritis 1:

• Continue current systemic therapy and treat with topical corticosteroids first rather than immediately switching biologics 1
• Only escalate systemic therapy if: frequent recurrent episodes occur, topical steroids cause complications (glaucoma, cataracts), or isolated episode doesn't resolve 1

Escalation Criteria for Systemic Therapy

Add systemic immunosuppression if 1, 3, 4:

• Inflammation persists despite 3 months of topical therapy
• Requires >1-2 drops/day prednisolone acetate 1% for >2-3 months to maintain control 3, 1
• Develops corticosteroid-induced complications (glaucoma, cataracts) 1, 3
• Poor prognostic factors present: bilateral disease, young age, complications at presentation 4

Systemic Treatment Hierarchy

First-line systemic agent 1, 4, 1:

• Methotrexate: Subcutaneous route preferred over oral 1
• Dose: Standard dosing for uveitis (typically 15-25 mg weekly)

Second-line (methotrexate failure/intolerance) 1, 4, 1:

• Monoclonal antibody TNF inhibitors (adalimumab > infliximab) 4, 8
• Strongly avoid etanercept—ineffective and may paradoxically worsen uveitis 4, 8

For severe sight-threatening CAU with complications 1:

• Start methotrexate + monoclonal TNF inhibitor simultaneously rather than sequential monotherapy 1

Third-line options (failed 2 TNF inhibitors at escalated doses) 1:

• Abatacept or tocilizumab (biologics) 1
• Mycophenolate, leflunomide, or cyclosporine (non-biologics) 1

Monitoring Requirements

During active treatment 3, 1:

• Ophthalmology exam within 1 month when tapering topical steroids 3
• Exam within 2 months when changing systemic therapy 3
• Minimum every 3 months on stable therapy 3

Treatment goals 4, 1:

• Zero anterior chamber cells
• Discontinue topical steroids due to glaucoma/cataract risk 3, 1
• Maintain 2 years of inactive disease off topical steroids before tapering systemic therapy 4

Critical Pitfalls to Avoid

1. Do not delay ophthalmology referral for patients with pain, photophobia, or vision changes—permanent vision loss can occur 1, 2

2. Do not use etanercept for uveitis treatment—it is ineffective and contraindicated 4, 8, 9

3. Do not continue topical steroids >3 months without adding systemic therapy if disease remains active 3, 1

4. Do not perform extensive laboratory workup without clinical guidance—tailor testing to presentation 5, 6

5. For HLA-B27+ spondyloarthritis patients: Educate about AAU warning signs (pain, redness, photophobia) to reduce treatment delays 1

6. Taper topical steroids before systemic therapy when disease is controlled on both 1